Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

BRLIR - Brilliant Acquisition Corp - Tradeable Rights - July 2020


Close
0.4501
0.150   33.348%

Share volume: 1,136,776
Last Updated: Fri 22 Dec 2023 10:00:00 PM CET

PREVIOUS CLOSE
CHG
CHG%

$0.30
0.15
50.03%
This ticker is disabled and data are no longer maintained and up to date.
Performance
5 Days
17.36%
1 Month
0   0%
3 Months
-5.00%
6 Months
-4.81%
1 Year
-2.11%
2 Year
-52.50%
Key data
Stock price
$0.45
P/E Ratio 
0.00
DAY RANGE
$0.45 - $0.45
EPS 
$0.00
52 WEEK RANGE
$0.02 - $0.30
52 WEEK CHANGE
-$0.02
MARKET CAP 
20.555 M
YIELD 
N/A
SHARES OUTSTANDING 
1.816 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$15,637
AVERAGE 30 VOLUME 
$9,717
Company detail
CEO:
Region: US
Website:
Employees: 898
IPO year: -
Issue type:
Market: XNAS
Industry:
Sector:

genedx was founded in 2000 by two scientists from the national institutes of health (nih) to address the needs of patients and clinicians in diagnosing rare inherited disorders. currently, genedx offers testing for more than 400 rare mendelian disorders, and gene panels for inherited cardiac disorders, inherited cancer syndromes, neurological disorders, and mitochondrial disorders. in addition, genedx also offers whole exome sequencing and whole genome chromosomal microarray testing. our highly trained and experienced physicians, geneticists, and genetic counselors work as a team to bring gene discoveries to clinical medicine for use in direct patient care. for more information, please visit our website at www.genedx.com

Recent news